TARA heads into its May 1 Q1 results with a notable gap between elevated short positioning and a Street that is uniformly — and aggressively — bullish.
Short interest has climbed sharply in recent days, jumping nearly 10% in a single session on April 24 to reach 14.1% of the free float. That follows a period of partial covering through mid-April, when shorts had eased back from earlier highs above 18% of float in late March. Utilization, at roughly 10%, is well below its 52-week peak of 28%, so the borrow market is far from stressed. Cost to borrow has also collapsed — down more than 55% over the past month to just 0.40% — signalling no meaningful squeeze pressure despite the uptick in shares short. Options traders are leaning decidedly toward calls: the put/call ratio is running at 0.04, well below its 20-day average of 0.044, near the lowest reading of the past year, suggesting the options market holds little downside protection into the print.
The bull case on Protara rests almost entirely on TARA-002. Proponents point to a high complete response rate in BCG-naïve non-muscle invasive bladder cancer patients in the ADVANCED-2 Phase 2 trial, a simplified manufacturing workflow relative to competing treatments, and active FDA engagement that could reduce regulatory risk. JP Morgan initiated coverage in early March with an Overweight rating and a $27 target — the most recent addition to a coverage group where every analyst is bullish, with a consensus mean target around $25.70. Against a stock trading at $4.99, that implies potential upside of roughly 400%, which is an extraordinary gap. That said, the consensus is now more than 50 days old and the stock has drifted lower, so the target-to-price divergence partly reflects a sliding share price rather than fresh conviction.
Bears are less convinced. Their central concern is execution risk: the company relies on a non-sterile manufacturing process that carries contamination risk, BCG shortages may complicate trial enrollment and comparability, and questions remain about the trial's statistical powering. Insider activity adds a cautious footnote — the CEO, CFO, and founder have all made small net sales over the past three months, totalling just under $400,000 in value, though the transaction sizes are modest and may reflect routine plan-based selling rather than a directional call.
Past earnings have delivered wide swings in both directions — a 25% jump following the November 2025 release, and a flat-to-small decline after the March 2026 event. The May 1 print is therefore less about financial metrics and more about whether ADVANCED-2 trial data, any updated FDA dialogue, or pipeline news can bridge the gap between where the stock trades and where analysts believe it belongs.
See the live data behind this article on ORTEX.
Open TARA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
